Recommended Duration of Nystatin Treatment for Yeast Infections
Duration by Infection Type
- The Infectious Diseases Society of America recommends nystatin suspension (100,000 U/mL) 4-6 mL four times daily for 7-14 days for oral candidiasis (thrush) 1, 2
- The Infectious Diseases Society of America recommends nystatin pastilles (200,000 U each) 1-2 pastilles four times daily for 7-14 days for oral candidiasis (thrush) 1, 2
- The Infectious Diseases Society of America recommends nystatin 100,000-unit vaginal tablets for 14 days for uncomplicated vaginal candidiasis 3, 4
- The Infectious Diseases Society of America recommends nystatin intravaginal suppositories 100,000 units daily for 14 days for C. glabrata infections unresponsive to azoles 5
- The Infectious Diseases Society of America recommends nystatin treatment for 7-14 days, combined with proper denture disinfection for denture-related candidiasis 1, 2
- The Infectious Diseases Society of America strongly recommends disinfection of the denture in addition to antifungal therapy for denture-related candidiasis 2
Special Populations
- The Infectious Diseases Society of America recommends that the duration of nystatin treatment may need to be extended in immunocompromised patients 2
- The Infectious Diseases Society of America strongly recommends antiretroviral therapy alongside antifungal treatment for HIV-infected patients with recurrent oropharyngeal candidiasis 2
Treatment Response and Follow-up
- Clinical response to nystatin treatment should be evident within 48-72 hours for vaginal candidiasis 6
- Mycological cure typically occurs within 4-7 days for vaginal infections treated with nystatin 6
- If symptoms persist beyond the recommended treatment duration, reevaluation for possible resistant organisms or alternative diagnoses is warranted 1, 2
Common Pitfalls and Caveats
- Self-diagnosis of yeast vaginitis is unreliable and may lead to inappropriate treatment, according to the Infectious Diseases Society of America 6
- Nystatin is generally less effective than fluconazole for systemic or moderate-to-severe infections, as stated by the Infectious Diseases Society of America 1, 2